Category: News

Webinar on data-driven drug target discovery

Intomics is hosting a Diagnostic World webinar August 27th 10am EDT / 4pm CET.

In the talk we will share our approach to data-driven analysis of biological networks, and applications for drug target discovery.

Learning objectives:
1. How analysis of biological networks can improve outcomes of data-driven target discovery analyses
2. Why high-confidence protein interaction networks are an important supplement to pathways when interpreting biomedical data
3. How you can interpret results from omics data analyses to gain biological insights
4. Value of network analysis approach demonstrated through drug target identification benchmark and case study

Sign up for free, or get more information here:

Intomics releases COVID-19 network analysis

A team of our bioinformatics experts performed a COVID-19 study with the aim of gaining new therapeutic insights and identifying potential drug targets for COVID-19. To share our findings with the scientific community, we have made the results freely available via our inBio Discover™ platform.

On the project site you can read about our findings and approach to network analysis, or proceed to explore the regulated biological networks on your own.

Highlights from our work
To gain new therapeutic insights and identify potential drug targets for COVID-19, we used a network approach based on physical protein-protein interactions (inBio Map™) to find biological systems regulated as a whole in response to SARS-CoV-2 infection.

  1. We use gene expression data from SARS-CoV-2 -infected human cells to perform network-level analysis of the host transcriptional response.
  2. We find biological networks that as a whole are more regulated than what should be expected from the transcriptome background, even if individual members of the network are not strongly regulated.
  3. We point to molecular mechanisms being affected by the virus infection, that are not immediately obvious from investigating individually significantly regulated genes.
  4. We identify drug target candidates in the networks (6 targets with approved drugs and 29 with drugs in clinical trials). Our network-based approach identifies more than two times the number of drug targets candidates compared to the Blanco-Melo et al. list of differentially expressed genes.

Get in touch with us to learn more about these results and algorithms, and how Intomics can help you advance your biomedical or COVID-19 research.

Intomics to be part of the newly funded TRANSLATE project on personalized diabetes treatment

As part of the TRANSLATE project funded with 30 mill. kroner by the Innovation Fund Denmark, Intomics will develop a new software platform facilitating personalised treatment of diabetes patients.

More information can be found here:
Innovation Fund Denmark press release (in Danish)
MedWatch article (in Danish)
Novo Nordisk Foundation Center for Basic Metabolic Research (in English)

New publication on advanced text mining approaches to early drug target discovery

In collaboration with Novo Nordisk, Intomics recently published “Semantic text mining in early drug discovery for type 2 diabetes” in PLOS ONE, about application of text mining in early drug discovery. The paper describes a project where we ranked proteins according to disease relevant contexts from scientific literature, and then identified potential novel targets by looking for ‘high jumpers’, i.e. proteins that were recently mentioned in increasingly relevant disease contexts.

Launch of the inBio Discover™ protein-protein interaction platform

Today, our new web-based protein-protein interaction platform inBio Discover™ was released.

inBio Discover™ is a powerful tool with a wide range of applications in interpretation and visualization of biomedical big data in a systems biology context. inBio Discover™ is part of the inBio platform and builds upon the high coverage, high quality protein-protein interaction network inBio Map™.

inBio Discover™ enables you to search for proteins to learn about their interactions. You can easily perform enrichment-analysis with a wide range of biological annotations and value-added datasets, including your own protein lists.

inBio Discover™ helps you learn more about the biology represented in your networks via a range of customizable visualizations options.

Visit: to learn more

Intomics selected as one of Denmarks fastest growing companies of 2017

Every year Danish business newspaper ‘Børsen’ selects the fastest growing companies of Denmark in what is denoted the ‘Gazelle’-awards. Companies are selected based on objective financial criterias, one of them being a  >100 % growth during the last 4 consecutive years as reported in the annual financial statements.

Thomas Skøt Jensen, CEO and co-founder was one of Intomics participants at the ‘Gazelle’-awardshow: ”Intomics has been growing rapidly the last four years. By maintaining a strong focus on delivering world class bioinformatics solutions to existing and new customers in the pharmaceutical industry we fully expect to continue our growth-journey in 2018 and beyond.”